Intradialytic Parenteral Nutrition in Patients on Hemodialysis: A Multicenter Retrospective Study

Marta Arias‐Guillén(Hospital Clínic de Barcelona), Juan Carlos González(Institut de Seguretat Pública de Catalunya), Loreley Betancourt(Corporació Sanitària Parc Taulí), Elisabeth Coll(Puigvert Foundation), Sílvia Collado(Parc de Salut), Bàrbara Romano‐Andrioni(Hospital Clínic de Barcelona), Ascensión Lupiañez-Barbero, Julia Garro(Hospital Universitari Joan XXIII de Tarragona), Verónica Duarte(Hospital Terrassa), Jordi Soler-Majoral(Hospital Universitari Germans Trias i Pujol), Jordi Calabia Martínez(Hospital Universitari de Girona Doctor Josep Trueta)
Nutrients
November 24, 2024
Cited by 4Open Access
Full Text

Abstract

Background and Objective: To evaluate the effectiveness and safety of intradialytic parenteral nutrition (IDPN) on different nutritional outcomes. Methods: This was a retrospective analysis for a “routinely collected data bank” in a multicenter cohort, conducted on consecutive malnourished or at-risk of malnutrition patients with chronic kidney disease on hemodialysis who underwent IDPN with a three-in-one parenteral nutrition formula for a period ≥ 2 weeks. The primary endpoint was the mean change in the malnutrition inflammation score (MIS) score between baseline and the last follow-up visit on IDPN. Results: Fifty-six patients were included. The mean age was 72.4 ± 12.0 years, and 24 (42.9%) were women. In the overall study sample, MIS significantly decreased from 16.4 (95%CI: 15.3–17.65) at baseline to 14.3 (95%CI: 12.8–15.8) at the last follow-up visit on IDPN (p = 0.0019). Fifteen (26.8%) patients achieved a MIS reduction ≥ 5 points after IDPN. As compared to baseline, IDPN significantly reduced the proportion of patients with protein-energy wasting (PEW) (89.3% versus 66.1%, respectively, p = 0.0023). Regarding analytical parameters, serum albumin (p = 0.0003) and total proteins (p = 0.0024) significantly increased after IDPN administration. Throughout the study’s follow-up period, 45 (80.4%) patients reported experiencing some type of adverse event. Conclusions: IDPN was associated with a significant improvement in the nutritional profile. Notably, our research found that the administration of IDPN over a duration > 3 months significantly improved the nutritional status of patients evaluated by the MIS test.


Related Papers

No related papers found

Powered by citation graph analysis